Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

JazzPharmaceuticals

More Like This

PR Newswire associated0

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

PR Newswire associated0

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PR Newswire associated0

Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire associated0

Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference

Business Wire logo

ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

PR Newswire associated0

Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences

PR Newswire associated0

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024

Business Wire logo

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy